Avadel Pharmaceuticals plc
Market Cap
$2.12B
P/E Ratio
-1082.00
EPS
$-0.02
Dividend Yield
0.00%
52-Week Range
$6.38 — $23.57
Volume
35.02M
Avg Volume
2.42M
Beta
1.31
Get alerted when AVDL hits your target price.
Free — enter your email to get started
P/E (TTM)
-1082.00
Forward P/E
28.28
PEG Ratio
-11.49
P/S (TTM)
8.55
P/B (TTM)
21.39
P/FCF
63.78
EV/EBITDA
401.88x
EV/Sales
—
ROE (TTM)
-0.00%
ROA (TTM)
-0.00%
ROIC
0.01%
Gross Margin
0.94%
Operating Margin
0.02%
Net Margin
0.00%
Debt/Equity
0.38
Current Ratio
2.76
EPS Growth (YoY)
+1.01%
Revenue Growth (YoY)
+0.54%
EPS Growth (3Y)
+0.05%
EPS Growth (5Y)
-1.97%
Sales Growth (3Y)
+1.68%
Sales Growth (5Y)
+0.69%
EPS Est (This Year)
$0.77
EPS Est (Next Year)
$0.91
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$0.94
Hold
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $20.20(-6.7% upside)
Institutional %
14.02%
Inst. Net Change
1.73M
Insider Net Shares (90d)
-11112052
Outstanding Shares
98.15M
Float
91.56M
Free Float %
93.28%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
IE
Exchange
NASDAQ
IPO Date
1996-06-07
Employees
188
CEO
Gregory J. Divis Jr.
Index Membership
—
Website
https://www.avadel.com
Avadel Pharmaceuticals plc (AVDL) is a healthcare company in the drug manufacturers - specialty & generic industry listed on the NASDAQ. With a market capitalization of $2.12B, a P/E ratio of -1082.00, AVDL is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare AVDL against other stocks using dozens of fundamental and technical filters.
Avadel Pharmaceuticals plc (AVDL) has a trailing twelve-month (TTM) P/E ratio of -1082.00. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Avadel Pharmaceuticals plc (AVDL) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Avadel Pharmaceuticals plc (AVDL) has a market capitalization of $2.12 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Hold" rating on Avadel Pharmaceuticals plc (AVDL) with an average score of 3.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $20.20 implies 6.7% downside from the current price.